Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
[This corrects the article DOI: 10.1371/journal.pone.0234991.].
Main Author: | PLOS ONE Staff |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0241089 |
Similar Items
-
Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: Anna Burguin, et al.
Published: (2020-01-01) -
Correction: HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.
by: PLOS ONE Staff
Published: (2024-01-01) -
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
by: Sibylle Loibl, et al.
Published: (2022-09-01) -
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
by: Ansh Kapil, et al.
Published: (2024-05-01) -
PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
by: Abul Azad, et al.
Published: (2025-01-01)